No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ALNY240816C185000
- 57.00
- 0.000.00%
15min DelayTrading Jun 25 15:03 ET
0.00High0.00Low
0.00Open57.00Pre Close0 Volume73 Open Interest185.00Strike Price0.00Turnover55.16%IV2.61%PremiumAug 16, 2024Expiry Date50.85Intrinsic Value100Multiplier25DDays to Expiry6.15Extrinsic Value100Contract SizeAmericanOptions Type0.9630Delta0.0023Gamma4.49Leverage Ratio-0.0788Theta0.1222Rho4.32Eff Leverage0.0505Vega
Intraday
- 5D
- Daily
News
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
Ionis Pharmaceuticals Inc (NASDAQ:IONS) released results Monday from the completed multiple ascending dose (MAD) portion of the Phase 1/2 open-label study of ION582 in people with Angelman syndrome (
Alnylam Pharmaceuticals Is Maintained at Neutral by Cantor Fitzgerald
Alnylam Pharmaceuticals Is Maintained at Neutral by Cantor
Alnylam Pharmaceuticals Price Target Raised to $220.00/Share From $150.00 by Cantor Fitzgerald
Alnylam Pharmaceuticals Price Target Raised to $220.00/Share From $150.00 by Cantor
Express News | Cantor Fitzgerald Maintains Neutral on Alnylam Pharmaceuticals, Raises Price Target to $220
Market Sentiment Around Loss-Making Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
$100 Invested In This Stock 20 Years Ago Would Be Worth $4,100 Today
Alnylam Pharmaceuticals (NASDAQ:ALNY) has outperformed the market over the past 20 years by 12.59% on an annualized basis producing an average annual return of 21.02%. Currently, Alnylam
Comments
Jinta Hong, CFA
Background
As we enter the second half of 2024, the global financial landscape remains dynamic, influenced by international relations and economic policies. While major markets like the US, Japan, India, and parts of Europe have seen significant growth, Australia has faced challenges such as inflation and weak Chinese economic performance. The $S&P/ASX 200(.XJO.AU$ index reached a historic peak in April ...
Background
As we enter the second half of 2024, the global financial landscape remains dynamic, influenced by international relations and economic policies. While major markets like the US, Japan, India, and parts of Europe have seen significant growth, Australia has faced challenges such as inflation and weak Chinese economic performance. The $S&P/ASX 200(.XJO.AU$ index reached a historic peak in April ...
+7
82
7
2
$Annovis Bio(ANVS.US$ 22% Ph2/3 data reporting update
$Taysha Gene Therapies(TSHA.US$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US$ 14% Clinical programs update
$Jaguar Health(JAGX.US$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US$ 4% Ph1/2 positive data
$Delcath Systems(DCTH.US$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US$ 0...
$Taysha Gene Therapies(TSHA.US$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US$ 14% Clinical programs update
$Jaguar Health(JAGX.US$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US$ 4% Ph1/2 positive data
$Delcath Systems(DCTH.US$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US$ 0...
10
1
Read more
151652693 : There are many theories that do not touch the QE factor that caused the rise and harvest of global finance
151336027 :
151830249 :
151078437 :
151817588 :
View more comments...